Early hydroxychloroquine is associated with an increase of survival in COVID-19 patients: an observational study.

From OmniJournal
Revision as of 05:30, 22 July 2020 by Jtodaro2 (talk | contribs) (Created page with "Category:Article Category:Covid19 {| class="infobox" width=200px |class="publication"|'''Publication''' |- |Title || <ul>[https://www.preprints.org/manuscript/202005.0...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
  • Francisco Membrillo
  • German Ramirez-Olivencia
  • Miriam Estebanez
  • ...
  • Lucia Ballester
Journal Preprints.org
Date May 6, 2020

Observational study in Spain of early treatment with hydroxychloroquine in 166 COVID-19 patients showed a significant survival benefit in patients started on hydroxychloroquine in the mild stage of disease.

Patients were categorized into one of three groups at initial presentation: mild, moderate or severe. There was a significant survival benefit in the mild group compared to controls (1.8 times, p = 0.032) and a trend toward survival benefit in the moderate and severe groups (1.4 times and 1.6 times, respectively). Of note, the average time between symptom onset and treatment was 7 days.

Major Issues

No major issues identified.

Minor Issues

No minor issues identified.


This is another retrospective analysis that suggests efficacy of early treatment with hydroxychloroquine against COVID-19.

Article Revisions

None at this time.